Latest Breaking News On - Bos fund - Page 7 : comparemela.com
The Emerging Revival Of Psychedelics In Neuroscience
awaken.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from awaken.com Daily Mail and Mail on Sunday newspapers.
صناديق مواجع و صندقچـة مباهج !
iraqicp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iraqicp.com Daily Mail and Mail on Sunday newspapers.
В общественные советы двух госорганов объявлен дополнительный конкурс из-за гендерного дисбаланса – Новости из Кыргызстана – АКИpress
akipress.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from akipress.org Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term.
An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic syst
3T Biosciences Appoints Industry Veteran John Connolly as Interim CEO
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 /PRNewswire/ 3T Biosciences, an immunotherapy company, today announced that John Connolly, Ph.D. has been appointed as interim CEO. Together with the current leadership team, Dr. Connolly will lead the next round of financing with an emphasis on leveraging the company s 3T-TRACE™ technology for novel target discovery and therapeutic development.
John Connolly, Interim CEO, 3T Biosciences John has vast experience building and leading research and clinical programs in cell and gene therapy. It s an honor to have him guiding our program as we advance this business to the next phase of its evolution. Given his past and current experience, John has a successful track record of helping to raise capital and collaborating with innovative biopharmaceutical companies across the globe, stated Hanspeter Gerber, Ph.D.,